Skip to content

All Press Releases

PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION

Malmö, 26 November 2023 Pila Pharma AB (publ) ("Pila Pharma" or the "Company") has entered a research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group") on investigating the effect of XEN-D0501 on Abdominal Aorta Aneurism growth in mice. The hypothesis is that XEN-D0501 may reduce the chronic inflammation that leads to cardiovascular disease including…

Read more

PILA PHARMA PUBLISHES INFORMATION MEMORANDUM

Malmö, 17 November 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW…

Read more

Pila Pharma invites to After-Work investor meetings

Malmö, 7 November 2023 PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to an exciting evening of conversation when we host an after-work investor event near you! CEO & Founder Dorte X. Gram will elaborate on Pila Pharma and its innovative pill-treatment for obesity, diabetes and other related disorders. In the Q&A we’ll address the market for obesity &…

Read more

Contact us

Subscription for press releases
Back To Top